Kangmei Pharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Kangmei Pharmaceutical has a total shareholder equity of CN¥7.1B and total debt of CN¥46.7M, which brings its debt-to-equity ratio to 0.7%. Its total assets and total liabilities are CN¥14.2B and CN¥7.1B respectively. Kangmei Pharmaceutical's EBIT is CN¥262.1M making its interest coverage ratio -7.7. It has cash and short-term investments of CN¥773.6M.
Anahtar bilgiler
0.7%
Borç/özkaynak oranı
CN¥46.74m
Borç
| Faiz karşılama oranı | -7.7x |
| Nakit | CN¥773.59m |
| Eşitlik | CN¥7.08b |
| Toplam yükümlülükler | CN¥7.12b |
| Toplam varlıklar | CN¥14.19b |
Son finansal sağlık güncellemeleri
Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?
Oct 28
We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt
Jun 17Recent updates
Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?
Oct 28What Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) P/S Is Not Telling You
Aug 03We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt
Jun 17Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest
May 06Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price Is Out Of Tune With Revenues
Apr 10Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600518's short term assets (CN¥7.0B) exceed its short term liabilities (CN¥4.9B).
Uzun Vadeli Yükümlülükler: 600518's short term assets (CN¥7.0B) exceed its long term liabilities (CN¥2.2B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600518 has more cash than its total debt.
Borcun Azaltılması: 600518's debt to equity ratio has reduced from 119% to 0.7% over the past 5 years.
Borç Kapsamı: 600518's operating cash flow is negative, therefore debt is not well covered.
Faiz Kapsamı: 600518 earns more interest than it pays, so coverage of interest payments is not a concern.